A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
Latest Information Update: 11 Mar 2025
At a glance
- Drugs ICP-488 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors InnoCare Pharma
Most Recent Events
- 09 Mar 2025 Results presented in an InnoCare Pharma media release
- 09 Mar 2025 According to an InnoCare Pharma media release, data from this trial in patients with moderate-to-severe plaque psoriasis has been released at the 2025 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral presentation, is held from Mar 7 to 11 in Orlando, Florida, USA
- 28 Feb 2025 Status changed from active, no longer recruiting to completed.